Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on October 21, 2022. The report details the entry into a material definitive agreement regarding the company's trade receivables securitization facility.
Key Financial Metrics and Facility Details
The filing does not report revenue, profit, cash flow, or margins for a specific period. Instead, it outlines the terms of the amended securitization facility:
- Base Limit: $1,450 million.
- Seasonal Increase Option: Additional $250 million available during the first and fourth quarters, subject to bank approval.
- Term Extension: Extended by one year to October 21, 2025.
- Underlying Assets: Accounts receivable originated by AmerisourceBergen Drug Corporation (ABDC) and ASD Specialty Healthcare, LLC from pharmaceutical sales.
Material Changes Versus Prior Period
The Eighteenth Amendment to the Receivables Purchase Agreement introduced the following changes:
- Benchmark Transition: Substituted Term SOFR for LIBOR as the interest rate benchmark and established procedures for future benchmark selection.
- Term Extension: Extended the facility maturity date to October 21, 2025.
- Operational Updates: Added provisions for the return of erroneous payments and updated compliance requirements regarding sanctions and anti-money laundering laws.
- Technical Amendments: Implemented other minor technical adjustments.
Outlook, Risks, and Management Commentary
The facility is designed to provide additional liquidity and funding for the ongoing business needs of the Company and its subsidiaries. The Company serves as the performance guarantor for the obligations of ASD (as originator) and ABDC (as originator and servicer). The filing incorporates the full text of the amendment as Exhibit 10.1 for complete legal details. No specific forward-looking guidance or new risk factors were disclosed in this specific report beyond the standard operational risks associated with the facility.
Key Facts for Investor Verification
- Verify the impact of the LIBOR to Term SOFR transition on future interest expense.
- Confirm the utilization rate of the $1,450 million base limit and the $250 million seasonal option in subsequent quarterly reports.
- Review the full text of the Eighteenth Amendment (Exhibit 10.1) for specific covenants and default conditions.
- Note that the company name in the filing is AmerisourceBergen Corporation, which later became Cencora, Inc.